Login to Your Account



Answering The Call For Products, ViroPharma Shifting Gears Again

By Randall Osborne


Monday, January 26, 2004
It was déja vu, but not the same. In August 2002, when ViroPharma Inc.'s deal with Aventis Pharmaceuticals Inc. to develop Picovir (pleconaril) for the common cold ended - the arrangement was terminated by mutual consent, and ViroPharma's stock fell more than 25 percent - CEO Michel de Rosen told investors: "Today is the day when we begin to look forward again." (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription